Market Place
Sourcing Support
Novartis` $2.9B MorphoSys bet stumbles as safety delays filing
30 Oct 2024 //
FIERCE BIOTECH
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
12 Jul 2024 //
BUSINESSWIRE
MorphoSys to Delist from Frankfurt Stock Exchange Following Novartis Acquisition
20 Jun 2024 //
CONTRACT PHARMA
MorphoSys And Novartis Plan Merger Squeeze-Out Of Minority Shareholders
20 Jun 2024 //
BUSINESSWIRE
Erasca restructures; Novartis moves to complete MorphoSys deal
17 May 2024 //
BIOPHARMADIVE
Novartis Meets Conditions For $68/Share MorphoSys Acquisition
16 May 2024 //
GLOBENEWSWIRE
Novartis to buy radiology drug specialist Mariana for $1 billion
03 May 2024 //
REUTERS
Morphosys says takeover by Novartis on course after report of drug safety concern
30 Apr 2024 //
REUTERS
MorphoSys AG Reports First Quarter 2024 Financial Results
29 Apr 2024 //
BUSINESSWIRE
MorphoSys`s Pelabresib Myelofibrosis Data in ASCO Oral Session
24 Apr 2024 //
ACCESSWIRE
MorphoSys Boards Recommend Accepting Novartis Takeover Offer
11 Apr 2024 //
BUSINESSWIRE
Novartis tender offer for MorphoSys AG commences
11 Apr 2024 //
GLOBENEWSWIRE
Novartis begins tender offer for MorphoSys
11 Apr 2024 //
REUTERS
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis
22 Mar 2024 //
ACCESSWIRE
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results
13 Mar 2024 //
BUSINESSWIRE
German competition regulator clears path for Novartis takeover of MorphoSys
12 Mar 2024 //
REUTERS
Novartis to acquire cancer-centric MorphoSys for $2.9 bln
06 Feb 2024 //
PRESS RELEASE
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08 Jan 2024 //
PRESS RELEASE
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3
10 Dec 2023 //
BUSINESSWIRE
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Improvement
20 Nov 2023 //
BUSINESSWIRE
MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
15 Nov 2023 //
BUSINESSWIRE
MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results
09 Aug 2023 //
BUSINESSWIRE
MorphoSys AG Reports 1Q 2023 Financial Results
04 May 2023 //
BUSINESSWIRE
MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
BUSINESSWIRE
Invitation to MorphoSys` Full Year Results 2022 Conference Call on March 16
09 Mar 2023 //
ACCESSWIRE
MorphoSys Stops Pre-Clinical Research Programs; To Cut Jobs
03 Mar 2023 //
NASDAQ
MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
02 Mar 2023 //
ACCESSWIRE
MorphoSys CFO Sung Lee exits as shares suffer in market meltdown
23 Dec 2022 //
ENDPTS
Novartis pays $23M cash for preclinical MorphoSys program
08 Dec 2022 //
FIERCEBIOTECH
MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
16 Nov 2022 //
BUSINESSWIRE
MorphoSys to Share New Data on Pelabresib and Monjuvi in 14 Presentations at ASH
03 Nov 2022 //
ACCESSWIRE
MorphoSys to Share New Data on Pelabresib and Monjuvi®
03 Nov 2022 //
PRESS RELEASE
That secretive ARCH biotech with two antibodies from MorphoSys?
01 Nov 2022 //
ENDPTS
GSK, MorphoSys` Partner, Provides Update on ContRAst PIII Program for Otilimab
27 Oct 2022 //
ACCESSWIRE
MorphoSys Presents Preliminary Results from Phase 1/2 Study of (CPI-0209)
27 Oct 2022 //
ACCESSWIRE
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales
21 Oct 2022 //
ACCESSWIRE
MorphoSys shows Data from L-MIND Suggesting Response to Treatment with Monjuvi
28 Sep 2022 //
BUSINESSWIRE
MorphoSys appoints Tim Demuth as new Chief R&D Officer
31 Aug 2022 //
MORPHOSYS
MorphoSys Appoints Tim Demuth as New Chief R&D Officer
31 Aug 2022 //
BUSINESSWIRE
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
03 Aug 2022 //
BUSINESSWIRE
Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results
28 Jul 2022 //
PRESS RELEASE
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales for 2022
26 Jul 2022 //
ACCESSWIRE
MorphoSys finds billion-dollar home for unwanted assets
16 Jun 2022 //
FIERCEBIOTECH
I-Mab Partner MorphoSys Announces License Agreements for Felzartamab and TJ210
15 Jun 2022 //
PRNEWSWIRE
MorphoSys and HIBio Enter Into Agreements for Felzartamab and MOR210
14 Jun 2022 //
BUSINESSWIRE
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi
13 Jun 2022 //
BUSINESSWIRE
MorphoSys Presents Multiple Analyses of the MANIFEST PII Trial for Pelabresib
10 Jun 2022 //
BUSINESSWIRE
MorphoSys to Present New Data on Pelabresib and Monjuviat EHA and ASCO
12 May 2022 //
BUSINESSWIRE
MorphoSys AG Reports First Quarter 2022 Financial Results
04 May 2022 //
BUSINESSWIRE
MorphoSys AG Reports Q4 and FY 2021 Financial Results
16 Mar 2022 //
BUSINESSWIRE
MorphoSys cuts R&D from Constellation deal to focus on cancer drugs
11 Mar 2022 //
MEDCITYNEWS
MorphoSys and Incyte Announce Additional Real-World Evidence Results RE-MIND2
11 Dec 2021 //
BUSINESSWIRE
MorphoSys, Incyte Show Additional Real-World Data from RE-MIND2 Study
11 Dec 2021 //
BUSINESSWIRE
MorphoSys presents interim results from M-PLACE study with felzartamab
04 Nov 2021 //
MORPHOSYS
MorphoSys to present MANIFEST and RE-MIND2 data hematology-oncology ASH
04 Nov 2021 //
MORPHOSYS
MorphoSys AG announces Monjuvi(R) Sales for the First Nine Months
02 Nov 2021 //
MORPHOSYS
MorphoSys AG: First Patient Dosed in Phase 2 of Felzartamab in IgAN
20 Oct 2021 //
BIOSPACE
Incyte and MorphoSys announce European Commission clearance of Minjuvi ®
26 Aug 2021 //
BUSINESSWIRE
